We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

10 hedge funds and large institutions have $33.1M invested in ESSA Pharma in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more capital invested

Capital invested by funds: $23.6M → $33.1M (+$9.51M)

0% more funds holding

Funds holding: 10 → 10 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.02% less ownership

Funds ownership: 1.9% → 1.88% (-0.02%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
10
Holders Change
–
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$143

Top Sellers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
-$289K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.3K

EPIX Hedge Fund Activity: Q1 2017 in Review

10 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q1 2017, worth a combined $33.1M — up 40% from $23.6M a quarter earlier.

Fund positioning in EPIX was balanced in Q1 2017: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $143. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $289K sold.

  • 10 institutional investors held ESSA Pharma (EPIX) as of Q1 2017, unchanged from Q4 2016.
  • Funds reported $33.1M of ESSA Pharma stock for Q1 2017, up 40% quarter-over-quarter.
  • 1 fund opened new ESSA Pharma positions in Q1 2017 and 1 closed out, a net change of 0 holders.
  • The largest ESSA Pharma buyer in Q1 2017 was Toronto Dominion Bank, an estimated $143 added.
  • The largest ESSA Pharma seller in Q1 2017 was DAFNA Capital Management, an estimated $289K sold.

Based on aggregated 13F filings for Q1 2017.